Download PDF
Semin Respir Crit Care Med 2008; 29(4): 361-383
DOI: 10.1055/s-2008-1081280
© Thieme Medical Publishers

Radiofrequency Ablation of Pulmonary Malignancies

Steven C. Rose1
  • 1Department of Radiology, University of California San Diego Medical Center, San Diego, California
Further Information

Publication History

Publication Date:
23 July 2008 (online)

    Permissions and Reprints

ABSTRACT

Several surgical, medical, irradiative, and image-guided focal ablative therapies are available for patients with primary non-small-cell lung cancer (NSCLC) or pulmonary metastases. The most appropriate therapy depends on cell type; the size, location, and number of tumors; the degree of local tumor spread and regional and distant metastases; the cardiopulmonary and functional status of the patient; symptoms; and therapeutic goals and desires of the patients and their caregivers. When potential cure or survival benefit is the goal, the most appropriate patients for radiofrequency (RF) ablation are those with stage I NSCLC or a few peripheral metastases limited to the lungs that are preferably less than 3 cm diameter, and who are not candidates for surgical resection. Because many of these patients will demonstrate local residual viable tumor or develop metastases or new primary tumors elsewhere, lifelong imaging surveillance with potential reintervention is warranted. When relief of tumor-related symptoms is the therapeutic goal, RF ablation may be applied to larger more advanced tumors with a reasonable expectation of improvement in a significant proportion of this population.

In addition to judicious case selection, precise device placement with careful attention to RF ablation technique is essential to achieve optimized outcome with respect to complete tumor necrosis and avoidance of injury to critical nontargeted structures. Awareness of potential complications, use of techniques to minimize the probability of complications, and early recognition with aggressive management of complications are paramount to maintaining a satisfactory safety profile for RF ablation.

KEYWORDS

Lung cancer - radiofrequency ablation - image-guided therapy - metastases - lung

REFERENCES

  • 1 Jemal A, Taylor M, Ward E et al.. Cancer statistics 2005.  CA Cancer J Clin. 2005;  55 10-30
    CrossrefPubMedGoogle Scholar
  • 2 Boring C C, Squires T S, Tong T, Montgomery S. Cancer statistics, 1994.  CA Cancer J Clin. 1994;  44 7-26
    PubMedGoogle Scholar
  • 3 American Cancer Society .Cancer Facts and Figures 2005. Atlanta, GA; American Cancer Society 2005
    Google Scholar
  • 4 Mountain C F. A new international staging system for lung cancer.  Chest. 1986;  89(Suppl) 225S-233S
    PubMedGoogle Scholar
  • 5 Mountain C F. Revisions in the International System for Staging Lung Cancer.  Chest. 1997;  111 1710-1717
    CrossrefPubMedGoogle Scholar
  • 6 Non-Small Cell Lung Cancer (PDQ®): Treatment. Washington, DC; National Cancer Institute, U.S. National Institutes of Health http://[www.cancer.gov/cancertopics/PDQ/treatments/non-smallcelllung/patients]
    Google Scholar
  • 7 Lung. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York; Springer 2002: 167-181
    Google Scholar
  • 8 Rose S C, Thistlethwaite P A, Sewell P E, Vance R B. Lung cancer and radiofrequency ablation.  J Vasc Interv Radiol. 2006;  17 927-951
    CrossrefPubMedGoogle Scholar
  • 9 Figlin R A, Holmes E C, Turrisi III A T. Neoplasms of the lung, pleura, and mediastinum. In: Haskell CM Cancer Treatment. 4th ed. Philadelphia; WB Saunders 1995: 385-413
    Google Scholar
  • 10 Spira A, Ettinger D S. Multidisciplinary management of lung cancer.  N Engl J Med. 2004;  350 379-392
    CrossrefPubMedGoogle Scholar
  • 11 Burt M, Martini N, Ginsberg R J. Surgical treatment of lung carcinoma. In: Baue AE Glenn's Thoracic and Cardiovascular Surgery. 6th ed. Stamford, CT; Appleton & Lange 1996: 421-443
    Google Scholar
  • 12 Ginsberg R J, Port J L. Surgical therapy of stage I and non-T3 NO stage II non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD Lung Cancer: Principles and Practice. 2nd ed. Philadelphia; Lippincott Williams & Wilkins 2000: 682-693
    Google Scholar
  • 13 Ihde D C, Pass H I, Glatstein E. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA Cancer Principles and Practice of Oncology. 5th ed. Philadelphia; Lippincott-Raven 1997: 911-949
    Google Scholar
  • 14 Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001.  Eur Respir J Suppl. 2002;  35 61s-70s
    PubMedGoogle Scholar
  • 15 Ginsberg R J, Rubinstein L V. Randomized trial of lobectomy versus limited resection for T1 NO non-small cell lung cancer. Lung Cancer Study Group.  Ann Thorac Surg. 1995;  60 615-623
    CrossrefPubMedGoogle Scholar
  • 16 Boysen P G, Block A J, Moulder P V. Relationship between preoperative pulmonary function tests and complications after thoracotomy.  Surg Gynecol Obstet. 1981;  152 813-815
    PubMedGoogle Scholar
  • 17 Winton T, Livingston R, Johnson D for the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR et al.. 10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.  N Engl J Med. 2005;  352 2589-2597
    CrossrefPubMedGoogle Scholar
  • 18 Johnson D H, Fehrenbacher L, Novotny W F et al.. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.  J Clin Oncol. 2004;  22 2184-2191
    CrossrefPubMedGoogle Scholar
  • 19 Sandler A, Gray R, Perry M C et al.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.  N Engl J Med. 2006;  355 2542-2550
    CrossrefPubMedGoogle Scholar
  • 20 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leukovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedGoogle Scholar
  • 21 Shepherd F A, Pereira J R, Cinleanu T et al.. Erlotinib in previously treated non-small-cell lung cancer.  N Engl J Med. 2005;  353 123-132
    CrossrefPubMedGoogle Scholar
  • 22 Willis R A. Secondary tumours of the lungs. In: The Spread of Tumours in the Human Body. London; Butterworth 1973: 167-174
    Google Scholar
  • 23 Morgan-Parkes J H. Metastases: mechanisms, pathways, and cascades.  AJR Am J Roentgenol. 1995;  164 1075-1082
    PubMedGoogle Scholar
  • 24 Pastorino U, Buyse M, Friedel G The International Registry of Lung Metastases, Writing Committee et al.. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.  J Thorac Cardiovasc Surg. 1997;  113 37-49
    CrossrefPubMedGoogle Scholar
  • 25 Saito Y, Omiya H, Kohno K et al.. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment.  J Thorac Cardiovasc Surg. 2002;  124 1007-1013
    CrossrefPubMedGoogle Scholar
  • 26 Pass H I, Donington J S. Metastatic cancer to the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA Cancer. Principles and Practice of Oncology. Philadelphia; Lippincott-Raven 1997: 2536-2551
    Google Scholar
  • 27 Chen P W, Pass H I. Indications for resection of pulmonary metastases. In: Baue AE. Glenn's Thoracic and Cardiovascular Surgery. 6th ed. Stamford, CT; Appleton & Lange 1996: 499-510
    Google Scholar
  • 28 Landreneau R J, De Giacomo T, Mack M J et al.. Therapeutic video-assisted thoracoscopic surgical resection of colorectal pulmonary metastases.  Eur J Cardiothorac Surg. 2000;  18 671-677
    CrossrefPubMedGoogle Scholar
  • 29 Mountain C F, McMurtrey M J, Hermes K E. Surgery for pulmonary metastasis: a 20-year experience.  Ann Thorac Surg. 1984;  38 323-330
    CrossrefPubMedGoogle Scholar
  • 30 Friedel G, Pastorino U, Ginsberg R J et al.. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases.  Eur J Cardiothorac Surg. 2002;  22 335-344
    CrossrefPubMedGoogle Scholar
  • 31 Nahum Goldberg S, Dupuy D E. Image-guided radiofrequency tumor ablation: challenges and opportunities–part I.  J Vasc Interv Radiol. 2001;  12 1021-1032
    PubMedGoogle Scholar
  • 32 McGahan J P, Browning P D, Brock J M, Tesluk H. Hepatic ablation using radiofrequency electrocautery.  Invest Radiol. 1990;  25 267-270
    CrossrefPubMedGoogle Scholar
  • 33 McGahan J P, Brock J M, Tesluk H, Gu W Z, Schneider P, Browning P D. Hepatic ablation with use of radio-frequency electrocautery in the animal model.  J Vasc Interv Radiol. 1992;  3 291-297
    CrossrefPubMedGoogle Scholar
  • 34 Kruskal J B, Oliver B, Huertas J C, Goldberg S N. Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tissue in mice.  J Vasc Interv Radiol. 2001;  12 1193-1201
    PubMedGoogle Scholar
  • 35 Shirabe K, Takenaka K, Gion T et al.. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin.  Br J Surg. 1997;  84 1077-1080
    CrossrefPubMedGoogle Scholar
  • 36 Elias D, Cavalcanti A, Sabourin J C et al.. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin.  Eur J Surg Oncol. 1998;  24 174-179
    PubMedGoogle Scholar
  • 37 Dodd III G D, Frank M S, Aribandi M, Chopra S, Chintapalli K N. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations.  AJR Am J Roentgenol. 2001;  177 777-782
    PubMedGoogle Scholar
  • 38 Chen M H, Yang W, Yan K et al.. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients–mathematic model, overlapping mode, and electrode placement process.  Radiology. 2004;  232 260-271
    CrossrefPubMedGoogle Scholar
  • 39 Grieco C A, Simon C J, Mayo-Smith W W, DiPetrillo T A, Ready N E, Dupuy D E. Percutaneous Image-Guided Thermal Ablation and Radiation Therapy: Outcomes of Combined Treatment for 41 patients with Inoperable Stage I/II Non-Small Cell Lung Cancer.  J Vasc Interv Radiol. 2006;  17 1117-1124
    CrossrefPubMedGoogle Scholar
  • 40 Lee J M, Jin G Y, Goldberg S N et al.. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report.  Radiology. 2004;  230 125-134
    CrossrefPubMedGoogle Scholar
  • 41 Chin M C, Rosenqvist M, Lee M A, Griffin J C, Langberg J J. The effect of radiofrequency catheter ablation on permanent pacemakers: an experimental study.  Pacing Clin Electrophysiol. 1990;  13 23-29
    CrossrefPubMedGoogle Scholar
  • 42 Tong N Y, Ru H J, Ling H Y, Cheung Y C, Meng L W, Chung P C. Extracardiac radiofrequency ablation interferes with pacemaker function but does not damage the device.  Anesthesiology. 2004;  100 1041
    CrossrefPubMedGoogle Scholar
  • 43 Lencioni R, Crocetti L, Cioni R, Franchini C, Angeletti C A, Bartolozzi C. Radiofrequency ablation of lung tumors: value of multiplanar CT imaging for optimizing treatment protocol.  Radiology (p). 2003;  229(suppl) 548
    PubMedGoogle Scholar
  • 44 Goldberg S N, Solbiati L, Halpern E F, Gazelle G S. Variables affecting proper system grounding for radiofrequency ablation in an animal model.  J Vasc Interv Radiol. 2000;  11 1069-1075
    CrossrefPubMedGoogle Scholar
  • 45 Friedman M, Mikityansky I, Kam A et al.. Radiofrequency ablation of cancer.  Cardiovasc Intervent Radiol. 2004;  27 427-434
    PubMedGoogle Scholar
  • 46 Ahmed M, Liu Z, Afzal K S et al.. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model.  Radiology. 2004;  230 761-767
    CrossrefPubMedGoogle Scholar
  • 47 Gadaleta C, Mattioli V, Colucci G et al.. Radiofrequency ablation of 40 lung neoplasms: preliminary results.  AJR Am J Roentgenol. 2004;  183 361-368
    CrossrefPubMedGoogle Scholar
  • 48 Bojarski J D, Dupuy D E, Mayo-Smith W W. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors.  AJR Am J Roentgenol. 2005;  185 466-471
    CrossrefPubMedGoogle Scholar
  • 49 Sewell Jr P E. Percutaneous radiofrequency ablation of primary and secondary pulmonary malignancies using CT guidance.  Radiology. 2000;  217(Suppl P) 291
    PubMedGoogle Scholar
  • 50 Yamamoto A, Nakamura K, Matsuoka T et al.. Radiofrequency ablation in a porcine lung model: correlation between ct and histopathologic findings.  AJR Am J Roentgenol. 2005;  185 1299-1306
    CrossrefPubMedGoogle Scholar
  • 51 Sewell Jr P E, Vance R B, Wang Y D. Assessing radiofrequency ablation of non-small cell lung cancer with positron emission tomography (PET).  Radiology. 2000;  217(Suppl P) 334
    PubMedGoogle Scholar
  • 52 Akeboshi M, Yamakado K, Nakatsuka A et al.. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response.  J Vasc Interv Radiol. 2004;  15 463-470
    CrossrefPubMedGoogle Scholar
  • 53 Goldberg S N, Gazelle G S, Compton C C, McLoud T C. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications.  Acad Radiol. 1995;  2 776-784
    PubMedGoogle Scholar
  • 54 Morrison P R, van Sonnenberg E, Shankar S et al.. Radiofrequency ablation of thoracic lesions, I: Experiments in the normal porcine thorax.  AJR Am J Roentgenol. 2005;  184 375-380
    PubMedGoogle Scholar
  • 55 Nomori H, Imazu Y, Watanabe K et al.. Radiofrequency ablation of pulmonary tumors and normal lung tissue in swine and rabbits.  Chest. 2005;  127 973-977
    CrossrefPubMedGoogle Scholar
  • 56 Goldberg S N, Gazelle G S, Compton C C, Mueller P R, McLoud T C. Radio-frequency tissue ablation of VX2 tumor nodules in the rabbit lung.  Acad Radiol. 1996;  3 929-935
    CrossrefPubMedGoogle Scholar
  • 57 Lee J M, Jin G Y, Li C A et al.. Percutaneous radiofrequency thermal ablation of lung VX2 tumors in a rabbit model using a cooled tip-electrode: feasibility, safety, and effectiveness.  Invest Radiol. 2003;  38 129-139
    CrossrefPubMedGoogle Scholar
  • 58 Miao Y, Ni Y, Bosmans H et al.. Radiofrequency ablation for eradication of pulmonary tumor in rabbits.  J Surg Res. 2001;  99 265-271
    CrossrefPubMedGoogle Scholar
  • 59 Ahrar K, Price R E, Wallace M J et al.. Percutaneous radiofrequency ablation of lung tumors in a large animal model.  J Vasc Interv Radiol. 2003;  14 1037-1043
    PubMedGoogle Scholar
  • 60 Tominaga J, Miyachi H, Tekase K et al.. Time-related changes in computed tomographic appearance and pathologic findings after radiofrequency ablation of the rabbit lung: preliminary experimental study.  J Vasc Interv Radiol. 2005;  16 1719-1726
    PubMedGoogle Scholar
  • 61 Dupuy D E, Zagoria R J, Akerley W, Mayo-Smith W W, Kavanagh P V, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung.  AJR Am J Roentgenol. 2000;  174 57-59
    PubMedGoogle Scholar
  • 62 Herrera L J, Fernando H C, Perry Y et al.. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates.  J Thorac Cardiovasc Surg. 2003;  125 929-937
    CrossrefPubMedGoogle Scholar
  • 63 Suh R D, Wallace A B, Sheehan R E, Heinze S B, Goldin J G. Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation–preliminary results.  Radiology. 2003;  229 821-829
    CrossrefPubMedGoogle Scholar
  • 64 Steinke K, King J, Glenn D, Morris D L. Radiologic appearance and complications of percutaneous computed tomography-guided radiofrequency-ablated pulmonary metastases from colorectal carcinoma.  J Comput Assist Tomogr. 2003;  27 750-757
    CrossrefPubMedGoogle Scholar
  • 65 Yasui K, Kanazawa S, Sano Y et al.. Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience.  Radiology. 2004;  231 850-857
    CrossrefPubMedGoogle Scholar
  • 66 Belfiore G, Moggio G, Tedeschi E et al.. CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer—a preliminary report of 33 patients.  AJR Am J Roentgenol. 2004;  183 1003-1011
    CrossrefPubMedGoogle Scholar
  • 67 Kang S, Luo R, Liao W, Wu H, Zhang X, Meng Y. Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours.  World J Surg Oncol. 2004;  2 30
    CrossrefPubMedGoogle Scholar
  • 68 Lencioni R A, Crocetti L, Glenn D W, Morris D L, Suh R D, Bartolozzi C. Radiofrequency Ablation of Pulmonary Tumors Responses Evaluation (RAPTURE) trial.  Radiology. 2004;  233(suppl) 657
    PubMedGoogle Scholar
  • 69 VanSonnenberg E, Shankar S, Morrison P R et al.. Radiofrequency ablation of thoracic lesions, II: Initial clinical experience—technical and multidisciplinary considerations in 30 patients.  AJR Am J Roentgenol. 2005;  184 381-390
    PubMedGoogle Scholar
  • 70 Fernando H C, De Hoyos A, Landreneau R J et al.. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates.  J Thorac Cardiovasc Surg. 2005;  129 639-644
    CrossrefPubMedGoogle Scholar
  • 71 Mack M G, Luder-Luhr T, Eichler K, Balzer J O, Lehnert T, Vogl T J. Bipolar radiofrequency ablation of lung metastases. Radiological Society of North America Annual Meeting, Radiology 2005 233(suppl): 81
    Google Scholar
  • 72 Nguyen C L, Scott W J, Young N A, Rader T, Giles L R, Goldberg M. Radiofrequency Ablation of Primary Lung Cancer: Results from an Ablate and Resect Pilot Study.  Chest. 2005;  128 3507-3511
    CrossrefPubMedGoogle Scholar
  • 73 Ambrogi M C, Fontanini G, Cioni R, Faviana P, Fanucchi O, Mussi A. Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: results of a pilot study.  J Thorac Cardiovasc Surg. 2006;  131 1002-1006
    PubMedGoogle Scholar
  • 74 Ambrogi M C, Lucchi M, Dini P et al.. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term.  Eur J Cardiothorac Surg. 2006;  30 177-183
    CrossrefPubMedGoogle Scholar
  • 75 Simon C J, Dupuy D E, Dipetrillo T A et al.. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients.  Radiology. 2007;  243 268-278
    CrossrefPubMedGoogle Scholar
  • 76 Yamakado K, Hase S, Matsuoka T et al.. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan.  J Vasc Interv Radiol. 2007;  18 393-398
    CrossrefPubMedGoogle Scholar
  • 77 Therasse P, Arbuck S G, Eisenhauer E A et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000;  92 205-216
    CrossrefPubMedGoogle Scholar
  • 78 Solbiati L, Goldberg S N, Ierace T, Dellanoce M, Livraghi T, Gazelle G S. Radio-frequency ablation of hepatic metastases: postprocedural assessment with a US microbubble contrast agent–early experience.  Radiology. 1999;  211 643-649
    PubMedGoogle Scholar
  • 79 Raman S S, Lu D S, Vodopich D J, Sayre J, Lassman C. Creation of radiofrequency lesions in a porcine model: correlation with sonography, CT, and histopathology.  AJR Am J Roentgenol. 2000;  175 1253-1258
    PubMedGoogle Scholar
  • 80 Choi D, Lim H K, Kim S H et al.. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results.  Radiology. 2000;  217 558-563
    PubMedGoogle Scholar
  • 81 Chopra S, Dodd III G D, Chintapalli K N, Leyendecker J R, Karahan O I, Rhim H. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT.  AJR Am J Roentgenol. 2001;  177 381-387
    PubMedGoogle Scholar
  • 82 Cioni D, Lencioni R, Rossi S et al.. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome.  AJR Am J Roentgenol. 2001;  177 783-788
    PubMedGoogle Scholar
  • 83 Meloni M F, Goldberg S N, Livraghi T et al.. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT.  AJR Am J Roentgenol. 2001;  177 375-380
    PubMedGoogle Scholar
  • 84 Kim S K, Lim H K, Kim Y H et al.. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings.  Radiographics. 2003;  23 107-121
    CrossrefPubMedGoogle Scholar
  • 85 Morimoto M, Nozawa A, Numata K et al.. Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation.  J Ultrasound Med. 2005;  24 273-283
    PubMedGoogle Scholar
  • 86 Sacks D, McClenny T E, Cardella J F, Lewis C A. Society of Interventional Radiology clinical practice guidelines.  J Vasc Interv Radiol. 2003;  14(9 Pt 2) S199-S202
    CrossrefPubMedGoogle Scholar
  • 87 Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Nishimura T. Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms.  J Vasc Interv Radiol. 2006;  17 1625-1629
    CrossrefPubMedGoogle Scholar
  • 88 Hiraki T, Tajiri N, Mimura H et al.. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors; incidence and risk factors.  Radiology. 2006;  241 275-283
    CrossrefPubMedGoogle Scholar
  • 89 Jin G Y, Lee J M, Lee Y C, Han Y M. Acute cerebral infarction after radiofrequency ablation of an atypical carcinoid pulmonary tumor.  AJR Am J Roentgenol. 2004;  182 990-992
    CrossrefPubMedGoogle Scholar
  • 90 Yamakado K, Akeboshi M, Nakatsuka A et al.. Tumor seeding following lung radiofrequency ablation: a case report.  Cardiovasc Intervent Radiol. 2005;  28 530-532
    CrossrefPubMedGoogle Scholar
  • 91 Steinke K, King J, Glenn D W, Morris D L. Percutaneous radiofrequency ablation of lung tumors with expandable needle electrodes: tips from preliminary experience.  AJR Am J Roentgenol. 2004;  183 605-611
    PubMedGoogle Scholar
  • 92 Kinney T B, Chen H T, Rose S C, Valji K, Roberts A C. Complications of thoracic intervention: evaluation of contributory factors.  J Vasc Interv Radiol. 2003;  14(Suppl) S89
    PubMedGoogle Scholar
  • 93 Okuma T, Matsuoka T, Yamamoto A et al.. Factors contributing to cavitation after CT-guided percutaneous radiofrequency ablation for lung tumors.  J Vasc Interv Radiol. 2007;  18 399-404
    CrossrefPubMedGoogle Scholar
  • 94 Hiraki T, Yasui K, Mimura H et al.. Radiofrequency ablation of metastatic mediastinal lymph nodes during cooling and temperature monitoring of the tracheal mucosa to prevent thermal tracheal damage: initial experience.  Radiology. 2005;  237 1068-1074
    CrossrefPubMedGoogle Scholar
  • 95 Rose S C, Fotoohi M, Levin D L, Harrell J H. Cerebral microembolization during radiofrequency ablation of lung malignancies.  J Vasc Interv Radiol. 2002;  13 1051-1054
    CrossrefPubMedGoogle Scholar
  • 96 Yamamoto A, Matsuoka T, Toyoshima M et al.. Assessment of cerebral microembolism during percutaneous radiofrequency ablation of lung tumors using diffusion-weighted imaging.  AJR Am J Roentgenol. 2004;  183 1785-1789
    CrossrefPubMedGoogle Scholar
  • 97 Ahrar K, Stafford R J, Tinkey P T et al.. Evaluation of cerebral microemboli during radiofrequency ablation of lung tumors in a canine model with use of impedance-controlled devices.  J Vasc Interv Radiol. 2007;  18 929-935
    CrossrefPubMedGoogle Scholar

Steven C RoseM.D. 

Department of Radiology 8756, University of California San Diego Medical Center

200 West Arbor Dr., San Diego, CA 92103-8756

Email: scrose@ucsd.edu